Accepted for publication 7 March 1996 Aqueous eyedrops supplied in multidose containers include suitable antimicrobial preservatives at appropriate concentrations, except when the preparation itself has adequate antimicrobial properties. These preservatives must be compatible with the other ingredients of the preparation, and must remain effective throughout the period of use of the eyedrops. ' Increasingly, it has become apparent that a small but significant number of patients are intolerant of preservatives,2' either because of ocular toxicity which may be due to the disease process itself, or because of hypersensitivity or allergy. It is for this reason that there is a small but significant clinical need for eyedrops to be prepared without added preservatives.
Unpreserved eyedrops are available in unit dose containers or vials (UDVs), and they are designed primarily for use in surgical situations. However, the practicality and expense of using UDVs in a domiciliary situation must be considered. Patients were the two eyedrops used in this part of the study. All subsequent preservative efficacy tests were carried out at 20C-8"C to reflect our requirement that in use unpreserved eyedrops should be refrigerated.
One ml aliquots of the inoculated product were removed at 0, 6, 24, and 48 hours and 7, 14, and 28 days. Each was added to 9 ml of 0.1 % peptone water containing polysorbate 80 1%, lecithin 0.5%, Triton X100 1%, and sodium thiosulphate 1% as preservative inactivity agents. The control preparations were similarly sampled at 0 hours to determine the viable counts of the cultures used and to confirm the suitability of the media used for their growth.
Further dilutions were made as necessary. One ml aliquots of all dilutions were incorporated in duplicate pour plates and incubated at 30'C-350C for 3 days for the bacteria, and at 20'C-250C for 5 days for the yeasts and moulds. After incubation, the number of colonies on each plate were counted and taking the dilution factor into account, the number of colony forming units (cfu) per ml of product were calculated.
Each of the eyedrops was diluted 10-fold, 100-fold, 1000-fold, and 10 000-fold, and 1 ml of each dilution was added to four out of a series of five petri dishes containing 100 viable organisms of one of the test organisms. The fifth petri dish acted as a control. Molten agar was added to each of the plates which were then incubated as described above and examined for growth. This procedure was repeated with each ofthe four test organisms to establish the validity of the recovery counts.
Unpreserved The EP criteria for evaluation of antimicrobial activity for ophthalmic preparations, EP (A) and EP (B), are given in terms of the log reduction in the number of viable microorganisms against the value obtained for the inoculum, and are summarised in give general recommendations for an in use storage life for the eyedrops tested. Colony counting is not a precision method, and considering that the criteria are given in integer logarithmic reduction values, a half log reduction value was taken to specify the requirement of 'no increase' (NI)." Results Atropine 1% eyedrops without preservative stored at either 20°C-25°C or 2°C-8°C failed to meet the EP (B) specification with respect to S aureus, as shown in Table 2 .
However, at 2°C-8°C, there is a greater reduction in C albicans and P aeruginosa, and the drops only just failed the EP (B) criterion in that S aureus in not reduced by 1 log in 24 hours. Table 3 shows that chloramphenicol 0.5% unpreserved eyedrops stored at room temperature failed the EP (A) criterion for P aeruginosa, S aureus, and C albicans, as well as failing the EP (B) criterion for P aeruginosa and S aureus. However, at 2°C-8°C, they satisfy EP (A) for C albicans and A niger, meet the EP (B) for P aeruginosa, while only just failing the EP (B) criterion in that S aureus is not reduced by 1 log in 24 hours.
Further efficacy testing was carried out only at 2°C-8°C, and results are reported in Table 4 in decreasing range of efficacy, with the first results being for unpreserved eyedrops showing the greatest degree of inherent antimicrobial activity.
Discussion
The results show a lower rate of replication of organisms in refrigerated samples, and this is reflected in the greater log reductions achieved. This confirms the importance of refrigeration of unpreserved aqueous eyedrops.
The results show that many unpreserved eyedrops have their own inherent antimicrobial activity and many even achieve criterion EP (A) against some micro-organisms. In ophthalmology, it is justifiable to accept the lower EP (B) criterion in cases including intolerance to preservatives as a result of allergy or hypersensitivity,'8 use in patients with a compromised epithelium,19 or use in patients requiring intensive or chronic antiglaucoma therapy.""9
The inability of unpreserved chloramphenicol 0.5% eyedrops to achieve the EP (B) standard against S aureus is surprising, as clinically this is usually the treatment of choice for S aureus infections! This inconsistency between in vitro and in vivo testing calls into question the validity of in vitro challenge testing, although the discrepancy could be explained by the bacteriostatic nature of chloramphenicol.
Several unpreserved eyedrops, including gentamicin, cyclopentolate, atropine, pilocarpine, and cefuroxime, show a satisfactory reduction in the level of micro-organisms within 7 days, but cefuroxime, gentamicin, and some strengths of pilocarpine showed an increase thereafter, confirming that a 7 day life should not be exceeded as recommended by some authors.'0 Eyedrops such as acetylcysteine, hypromellose, and sodium chloride 0.9% have less inherent antimicrobial activity, but they are normally used in intact eyes where there is less risk of ophthalmic infection from contaminated eyedrops than in damaged eyes. Eye-drops such as citrate 6.5% and potassium ascorbate are used in the treatment of chemical burns, where the use of topical antibiotics is mandatory.
Simple saline solutions and eyedrops containing phosphate buffers (for example, prednisolone) appear to have little inherent antimicrobial activity. Conversely, eyedrops which contain disodium edetate have an increased ability to reduce the level of P aeruginosa and therefore consideration must be given to the overall formulation of the products as well as the active ingredients.
Most of the eyedrops tested had least inherent antimicrobial action against S aureus, and this problem is also encountered with products which are preserved." " Additionally, plasmid resistance has been shown to inactivate certain preservatives, notably mercurials," so the inclusion of preservatives may not always resolve this dilemma.
To date there is no unequivocal clinical evidence to suggest that eyedrops formulated without a preservative are more likely to result in ocular infections than eyedrops formulated with a preservative. Our experience at Moorfields Eye Hospital over 19 years with the use and production of in excess of 1.3 million bottles of unpreserved eyedrops has shown the 7 day in use, refrigerated, storage life to be a safe and appropriate figure for normal domiciliary use.
Recommendations
Unpreserved eyedrops should be stored at 2°C-8°C after opening to reduce the rate of replication of any microbial contaminants. In general, a 7 day in use storage life is confirmed for eyedrops containing alkaloids or antibiotics once opened by patients in a domiciliary situation.
When deciding upon an in use storage life, consideration should be given to a number of factors, including whether the eyedrops are being used in intact or damaged eyes, whether they are being administered in conjunction with antibiotic therapy, or whether they are being used in a hospital or domiciliary setting. Even in a hospital setting, the risk factors in an acute hospital may be different from those in a long stay hospital. The onus remains on medical practitioners to ensure that unpreserved multidose eyedrops are only used in appropriate circumstances to ensure safe and effective therapy.
